Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS: NAVB. OMED, REGN, GHDX, SNTS, AVNR, VRTX, CYTK
NAVB
Navidea Biopharmaceuticals Announces Agreement with FDA on Special Protocol Assessments for NAV5001 Phase 3 Program
OMED
OncoMed Pharmaceuticals Granted Patent for Methods of Treating Cancer With Its Novel Wnt Pathway Targeting Antibody Vantictumab (OMP-18R5)
REGN
Regeneron Pharms initiated with a Outperform at Oppenheimer; tgt $300
7:14 AM ET 8/22/13 | Briefing.com
. Oppenheimer initiates REGN with a Outperform and price target of $300. They expect near-term growth to continue as Eylea gains broader adoption in wet AMD and expands into a new indication, DME, in 2014. They are focused on REGN727, a PCSK9 inhibitor that could fulfill a huge unmet need in hypercholesterolemia, representing another blockbuster opportunity. Given the strength of its pipeline and an unmatched platform for antibody discovery, they view REGN as a core Biotech holding with meaningful potential for upside.
GHDX
Updated St. Gallen International Breast Cancer Guidelines, for the Second Time, Recognize Oncotype DX® as the Only Validated Multi-Gene Test Able to Predict Chemotherapy Benefit
SNTS
Analyst: Leerink Swann Downgrade NASDAQ: SNTS Santarus Old: Outperform New: Market Perform
AVNR
Avanir Pharmaceuticals Announces Publication of 'PRISM' Pseudobulbar Affect Registry Findings
VRTX
Analysts' Actions: MSFT PCP TSLA VRTX ZNGA
CYTK
Cytokinetics publishes results from tirasemtiv Phase II trials in ALS patients
NEWS: HSP, SUPN
HSP
Still Bullish on Hospira
SUPN
SUPN Income Statement
MSTX is up over 2.90% on around 270,00o shares traded. 1/3 of the 10 day moving average of volume in just 1 1/4 hours of trading. Increase in volume could see an appreciation in share price.
NEWS: PDLI, GALE, INCY, ABT
PDLI
Entry into a Material Definitive Agreement, Creation of a Direct Financial Ob
GALE
Galena Biopharma Expands NeuVax(TM) Intellectual Property With European Allowance
INCY
REFILE-Incyte pancreatic cancer drug improves survival in mid-stage trial
ABT
Abbott Completes Acquisition of IDEV Technologies
EVENTS: MSTX
Mast Therapeutics (MSTX $0.41) has completed or is in the process of completing these events by the end of the year - into the beginning of 2014. Thusly there should be an appreciation in the value of the stock into possibly the mid $0.60s were the warrants can be exercised and definitely above $0.50 (price of public offering).
MAST THERAPEUTICS PRICES PUBLIC OFFERING OF UNITS
EVENTS:
Report data from tQT/QTc Study
Q3-Completed>>>MAST THERAPEUTICS REPORTS RESULTS FROM CLINICAL QT STUDY OF MST-188
Submit Applications for U.S. Government Funding for Phase 2 Study in Resuscitation of Shock following Major Trauma
Q3-2013
Request Orphan Designation for MST-188 for ALI in U.S.
Q3-2013
Initiate Nonclinical Proof-of-Concept Study in Heart Failure
Q3-2013
Open First Ex-U.S. Clinical Site in Phase 3 Study
Q4-2013
Initiate Phase 2 Study in ALI
Q4 2013/Q1 2014
MSTX touching it's 52-week low. Time to see which way this one goes?
Below is a Forbes link that states Pharmaceutical companies are spending an average of $5B per new drug. At also states that focussing on "ultra-rare diseases; treatments for such ailments can cost $200,000 or more per patient per year, and be highly lucrative." It then goes on to state "BioMarin, another orphan drug maker, spent just $134 million per drug." Of course BioMarin (BMRN) is intertwined with Catalyst Pharmaceutical Partners (CPRX).
Cost of Creating a New Drug
Another down day in the market, DOW has worst week of 2013.
DOW closes the week down around 2.2%.
NASDAQ closes the week down around 1.6%.
S&P 500 closes the week down around 2.1%.
Issues causing the down markets could include, but not limited to:
A Market Correction - coming off the all time highs, could easily continue next week.
Troubles in Egypt - over 600 confirmed deaths in protests.
Thoughts of Tempering - government debating slowing bond buying.
Treasury 10 Year Yields - closing around 2.84%, highest level in two years.
Mortgage Rates - rates have increased to 4.52% from 4.32% last week for a 30-year fixed and have increased to 3.54% from 3.38% last week for a 15-year fixed (according to BankRate). The increase could be because of the rise in the yield on the 10 Year T-Note; which it tends to follow.
Retailers - Walmart and other have revised estimates lower for the rest of year and into FY14.
Gold and Silver - both had incredible gains this week, almost as if the market were running into the precious metals.
*I have updated the America! Portfolio balance for week ending on Friday August 16, 2013
Most stocks are languishing around today with the DOW down around 180. Time to add? or possibly wait out the market correction since it has been two days in a row now.
Welcome to Shizane's Portfolio Tracker.
A board where I plan to be as transparent as I can be with buys and sells - reasonings for doing both.
I have never been paid by any company to promote their stock.
I hope you like the page now and in the future years to come.
Thanks for looking. If you have any questions just ask on the board or send me a private message!
Followers
|
1
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
66
|
Created
|
08/15/13
|
Type
|
Premium
|
Moderators |
TICKER | Reason for Purchase | Cost Basis | Purchase Date | Purchase Average Volume (10 day) | Sell Price | Sell Date | Gain / Loss (%) |
---|---|---|---|---|---|---|---|
MSTX | Catalyst Play Through 2013 | .42189 | 08/15/13 | 358,019 | 2/3 @ .431 1/3@.4201 | 08/28/13 09/03/13 | 2.91 .02 = 1.93 |
ZLCS | October readout of data / possible reverse split | .65 | 08/28/13 | 1,490,229 | .7114 | 08/30/13 | 7.19 |
NVAX | September 11, 2013 presentation @ICAA. September 12, 2013 presentaion @ Stifel Nicolaus September 24, 2013 annual "Analyst Meeting." $11 price target from Lazard. | 3.23 3.30 = 3.25 | 08/30/13 09/03/13 | 4,173,193 | 3.36 | 09/12/13 | 2.36 |
ETRM | Should be hearing about a possible ADCOM soon. | 1.20 | 09/16/13 | 700,000 | 1.23 | 09/23/13 | 2.5 |
Ticker | Reason for Purchase | Cost Basis | Purchase Date | Purchase Average Volume (10-day) | Sell Price | Sell Date | Gain / Loss (%) |
---|---|---|---|---|---|---|---|
TICKER | Reasons | First Observed Date | First Observed Price | Current Price* | First Observed Average Volume (10 day) | Current Average Volume (10 day) | Notes: |
---|---|---|---|---|---|---|---|
Label | Description |
---|---|
Info | Article and / or information on the topic listed |
News | News release on the ticker(s) mention |
Purchase | Bought a position in mention ticker |
Sold | Sold out of a postition in mention ticker |
Ticker | Update(s) and Insight(s) on stated ticker |
Update | Updates made to the iBox |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |